For instance, aberrant promoter methylation resulting in loss of MGMT expression has been demonstrated in approximately 40% of colorectal cancers and gliomas, as well as in 25% of lymphomas and non-small cell lung carcinomas 3. This evidence concerns the gene MGMT and central nervous system cancer.